| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Income (loss) before income tax expense (benefit) | 33,800 | 10,525 | -31,498 | -2,287 |
| Income tax expense (benefit) | 7,183 | 1,976 | -7,332 | - |
| Net income (loss) | 26,617 | 8,549 | -24,166 | -2,287 |
| Dividends on series a convertible preferred stock | 344 | 407 | 406 | 407 |
| Net income (loss) available to common shareholders | 26,273 | 8,142 | -24,572 | -2,694 |
| Basic income (loss) per share(in dollars per share) | 1.19 | 0.37 | -1.27 | -0.14 |
| Basic weighted-average shares outstanding (in shares) | 20,074,000 | 19,834,000 | 19,404,000 | 19,321,000 |
| Diluted income (loss) per share (in dollars per share) | 1.13 | 0.36 | -1.27 | -0.14 |
| Diluted weighted-average shares outstanding (in shares) | 21,093,000 | 20,308,000 | 19,404,000 | 19,321,000 |
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)